arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


|

Advancing the Treatment of Non-Small–Cell Lung Cancer:
Interpreting the Latest Data From 2014

Presented by the Johns Hopkins University School of Medicine.

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit: www.lillygrantoffice.com.

OVERVIEW
Nonsmall cell lung cancer (NSCLC) has a low overall survival rate, and it is difficult to treat due to tumor location, complex pathology, and variable histology. The treatment landscape for NSCLC is evolving, with the approval of several targeted therapies, including monoclonal antibodies that offer additional therapeutic options for patients. Specific assays for identifying mutations have been developed that can help clinicians diagnose and select ideal therapies for individual patients. Emerging targeted and immunotherapies with the potential to improve survival are currently in development, and this online enduring expert panel discussion will summarize and discuss these advances and analyze how best to integrate them into practice for clinicians treating patients with NSCLC. This activity is based on the latest updates presented at American Society of Clinical Oncology and other oncology meetings in 2014.

GOAL
To provide clinicians who treat and manage patients with non-small–cell lung cancer (NSCLC) with the most up-to-date and current information about the advances in targeted therapy, immunology, and other areas of supportive care. No prerequisites required.

TARGET AUDIENCE
This activity is designed for oncology specialists who treat and manage patients with non-small–cell lung cancer. No prerequisites required.

LEARNING OBJECTIVES
After completing this activity, the participant will demonstrate the ability to:
  • ANALYZE up-to-date evidence on currently available treatment options for NSCLC.
  • ASSESS the role of emerging targeted therapies in the treatment of NSCLC.
  • EVALUATE the role of emerging immunotherapies in the treatment of NSCLC.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

CME INFORMATION
Accreditation Statement — The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement — The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After reviewing this online activity, participants may receive a certificate by receiving a score of 70% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.

The estimated time to complete this activity: 90 minutes.

Release date: September 7, 2015. Expiration date: September 7, 2016.

PARTICIPATING FACULTY
Julie R. Brahmer, MD, MSc (Course Director)
Associate Professor of Oncology
Director of the Thoracic Oncology Program
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Heather Wakelee, MD
Associate Professor of Medicine, Oncology
Stanford University and Stanford Cancer Institute
Stanford, California

DISCLOSURE POLICIES
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Participating Faculty Disclosures
Julie Renee Brahmer, MD, reports receiving research grants from AstraZeneca and Bristol-Myers Squibb Company; and serving as a consultant for Bristol-Myers Squibb Company, Celgene, Eli Lilly & Company, and Merck & Co, Inc.

Heather Wakelee, MD, reports receiving grants/research support from AstraZeneca, Bristol-Myers Squibb Company, Celgene, Clovis Oncology, Eli Lilly & Company, Exelixis, Inc, F. Hoffmann-La Roche Ltd/Genentech, Inc, Novartis, Pfizer, Inc, Regeneron Pharmaceuticals, Inc, and Xcovery; and serving as a consultant for Peregrine Pharmaceuticals Inc.

No other faculty have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

Planner Disclosures
Julie Renee Brahmer, MD, reports receiving research grants from AstraZeneca, Bristol-Myers Squibb Company, and Merck & Co, Inc; and serving as a consultant for Celgene, Eli Lilly & Company, and Merck & Co, Inc.

David S. Ettinger, MD, reports serving as a consultant for AMAG Pharmaceuticals, ARIAD Pharmaceuticals, Inc, Biodesix, Inc, Boehringer Ingelheim GmbH, Eisai, Inc, Eli Lilly & Company, F. Hoffmann-La Roche Ltd/Genentech, Inc, Gilead Sciences, Inc, Helsinn Group. No other planners have indicated that they have any financial interests or relationships with a commercial entity.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion
No speaker has indicated that he/she will reference unlabeled/unapproved uses of drugs or products.

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)(Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY
Instructions
Please complete the preassessment, listen to the following presentation, and complete the postassessment and evaluation to receive CME credit for this activity. A certificate of participation will be available online immediately following successful completion of the activity.

Preassessment

Immunotherapy in Non-Small–Cell Lung Cancer (NSCLC): PD-1 Immune Checkpoint Blockade
Julie R. Brahmer, MD, MSc

Advances in Targeted Therapy
Heather Wakelee, MD

Advances in Other Therapies and Supportive Care
David S. Ettinger, MD, FACP, FCCP

Postassessment

procced to pretest




Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.